http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021521165-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04
filingDate 2019-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2021521165-A
titleOfInvention BCL6 inhibitor
abstract The present invention is a compound of formula I that functions as an inhibitor of BCL6 (B cell lymphoma 6) activity. (In the formula, X 1 , X 2 , R 1 , R 2 , R 30 , R 31 and ring A are each as defined herein). The present invention also relates to the processes for preparing these compounds and their use in the treatment of proliferative diseases such as cancer and other diseases or conditions associated with BCL6 activity with pharmaceutical compositions containing them. Regarding.
priorityDate 2018-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID417667042
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467205615
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412091437
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467585863
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468172950
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID146172125
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465525571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID156402425
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID146189144

Total number of triples: 42.